Volume 148, Issue 1, Pages 88-99 (January 2015) Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes  Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk, Stephen N. Thibodeau, Rodrigo Dienstmann, Justin Guinney, Brian M. Bot, Sabine Tejpar, Mauro Delorenzi, Richard M. Goldberg, Michelle Mahoney, Daniel J. Sargent, Steven R. Alberts  Gastroenterology  Volume 148, Issue 1, Pages 88-99 (January 2015) DOI: 10.1053/j.gastro.2014.09.041 Copyright © 2015 AGA Institute Terms and Conditions

Figure 1 (A) Stage III colon cancers were categorized into 5 subtypes based on mutations in BRAF (V600E) and KRAS (exon 2) and MMR status. BRAFV600Eand KRAS mutations were mutually exclusive. (B) DFS is shown by molecular subtype in patients treated in an adjuvant trial of FOLFOX-based chemotherapy. Gastroenterology 2015 148, 88-99DOI: (10.1053/j.gastro.2014.09.041) Copyright © 2015 AGA Institute Terms and Conditions

Figure 2 DFS by molecular subtypes among (A) proximal or (B) distal stage III colon cancers. DFS by molecular subtypes among patients with stage III colon cancer and (C) 1–3 metastatic regional lymph nodes (N1) or (D) 4 or more metastatic regional lymph nodes (N2). Gastroenterology 2015 148, 88-99DOI: (10.1053/j.gastro.2014.09.041) Copyright © 2015 AGA Institute Terms and Conditions

Figure 3 Independent cohort of stage III colon cancer patients used for external validation of the subtype classifier. DFS is shown for the individual subtypes. Gastroenterology 2015 148, 88-99DOI: (10.1053/j.gastro.2014.09.041) Copyright © 2015 AGA Institute Terms and Conditions